News

A large specialty pharmacy cohort supports sustained reductions in attack rates across HAE subtypes, including normal C1 inhibitor disease.

Updated international guidance reinforces early self-administered on-demand therapy and integrates newer kallikrein-targeted agents into routine HAE management.

New data show limited uptake of SBS-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease.

These retrospective cohort studies also showed the vaccine’s reduction of heart attack, stroke, and asthma/COPD flare-ups in patients with RSV.

These data, released by Lilly, suggest ixekizumab (Taltz) and tirzepatide (Zepbound) are more effective when used together versus ixekizumab monotherapy.

Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Stocker discusses the potential for a wearable patch to continuous drug measurement of vancomycin, especially in pediatric patients and outpatient settings.

This clip from the latest episode of the Skin of Color Savvy podcast highlights Kazemi's experiences as a dermatologist working to help underserved communities.

Rizik and Morris discuss the Heartflow PCI Navigator and its promising implications for patients – and how they manage that excitement while waiting for trial data.

Experts in nephrology explain the benefits of kidney transplantation, the evolving immunosuppression landscape, and evaluate the risk factors for donors.

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

Real world study shows significant 12- and 18-month attack rate reductions across HAE subtypes and baseline severities following berotralstat initiation.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims and Hers and the risks of compounding GLP-1 formulas.

MAJESTY, a phase 3 study evaluating obinutuzumab in primary membranous nephropathy, demonstrates positive efficacy and safety.

This Skin of Color Savvy episode featured Abrahem Kazemi, MD, who speaks on several notable experiences he had as a dermatologist.

A new study found no association between antibiotic class or number of classes in infancy and later allergic disease, reinforcing stewardship over substitution.

Stay updated with the latest healthcare breakthroughs, FDA actions and new phase 2 and 3 data, in this week’s essential news roundup.

In pediatric platelet transfusions, what counts as success depends on the clinical context and treatment goals, not just the platelet count.

Eichenfield speaks in this interview about several key takeaways drawn from her master class in pediatric dermatology at Maui Derm Hawaii.

Experts discuss shifting CKD detection upstream, improving albuminuria screening, and enabling earlier, risk-based intervention.

The FDA denied accelerated approval for bitopertin, citing a need for evidence on clinical benefit from the ongoing phase 3 APOLLO trial.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Ozempic’s approval in a higher-dose oral form and lingering concerns over compounded drugs.

Stocker discusses findings from a pilot phase trial with clinical insight into a wearable patch for continuous drug measurement of vancomycin.

This Heart Failure Awareness Week, revisit recent advancements and scope out the future of heart failure care with HCPLive.

Developers emphasize plain language, explicit next steps, and clear limits to ensure the PLCOm2012-based tool supports, rather than replaces, formal lung cancer screening.

This segment of an interview from Maui Derm Hawaii, featuring Mark Kaufmann, MD, highlights key advice on AI scribe use and billing effectiveness in dermatology practices.

Younossi emphasizes the need for NIT-based risk stratification for MASLD, citing his research supporting their widespread adoption across clinical settings.